KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $24.83.

A number of equities analysts recently weighed in on KALV shares. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday. Finally, TD Cowen started coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $12.07 on Friday. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50. The company has a market cap of $600.07 million, a P/E ratio of -3.32 and a beta of 0.76. The stock’s 50-day simple moving average is $10.41 and its 200 day simple moving average is $10.24.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were acquired at an average cost of $9.22 per share, with a total value of $134,261.64. Following the completion of the transaction, the insider now owns 5,012,796 shares in the company, valued at $46,217,979.12. The trade was a 0.29 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares of the company’s stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders bought 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in KALV. State Street Corp grew its position in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after buying an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter valued at $634,000. Vestal Point Capital LP grew its holdings in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. Barclays PLC grew its holdings in shares of KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 54,257 shares in the last quarter. Finally, Readystate Asset Management LP bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).